ClinicalTrials.gov
public full text
Public Domain
Optimalization of Nephroprotection Using N-Acetylcysteine
The main purpose of the study is find whether the addition of N-acetylcysteine (antioxidant) to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and AT-1 angiotensin II receptor blocker leads to the reduction of proteinuria, main prognostic marker of chronic kidney disease progression.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System#835886
- Optimalization of Nephroprotection Using Atorvastatin (Sortis)#841782
- Sevelamer in Proteinuric CKD#909038
- N-acetylcysteine Protects From Aminoglycosides Induced Nephrotoxicity#908256
- The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom#888394
Record · ID 1152783
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive